<DOC>
	<DOCNO>NCT00769314</DOCNO>
	<brief_summary>To demonstrate efficacy single dose acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus single dose match placebo primary vesicular lesion cold sore .</brief_summary>
	<brief_title>Phase 3 Clinical Study Treatment Cold Sore</brief_title>
	<detailed_description />
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>History recurrent herpes labialis lesion : At least 50 % previous episode produce classical lesion vesicular stage ( i.e . episode progress macula , papule , vesicle , crust heal ) ; Prodromal symptom ( itch , tingle , pain etc . ) precede herpes labialis lesion least 50 % previous herpes episodes Good general health ( ECOG &lt; 2 ) , immunocompetent Signed date write informed consent Women childbearing potential must effective contraception method More 50 % recurrence abort spontaneously past 12 month Primary herpes lesion outside lip ( e.g . nose , chin , etc . ) Abnormal perioral skin condition might affect normal course cold sore ( e.g . eczema , psoriasis… ) Oral diseases whose prodromal symptom may mimick herpes labialis , include recurrent oral aphthous disease Oral disease might interfere evaluation efficacy safety treatment , include gingivitis , parondotis , mucositis , oropharyngeal candidiasis… History infection know resistant acyclovir family agent Previous vaccination herpes Concomitant treatment likely interfere acyclovir Allergy acyclovir contain agent Immunocompromised condition , include HIV+ Unability properly understand protocol requirement , follow study procedure , complete patient diary start selfinitiation treatment Upper full partial denture acrylic border canine fossa Milk allergy known history hypersensitivity one component product Rare hereditary problem galactose intolerance . Lactase enzyme deficiency glucose galactose malabsorption Clinically significant abnormal level serum creatinine Patients whose occupation make unlikely return clinic within 24h treatment initiation Pregnancy breastfeed Investigational drug immunomodulator treatment 30 day prior randomisation Prior enrollment study Participation another therapeutic trial evaluate new drug could interfere evolution herpes labialis evaluation drug study within precede 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>